Figure 5.

TCR clonality significantly increased in all groups treated with PDS0101. TC-1 tumor bearing female C57BL/6J mice were treated with PBS control (100 µL s.c.), PDS0101 (s.c., 3 weekly doses starting on day 7), bintrafusp alfa (250 µg, i.p., days 7, 9, and 11), and/or NHS-IL12 (50 µg, s.c., day 7). Tumor infiltrating lymphocytes (TILs) were purified from whole tumor. DNA isolated from TILs was analyzed by Adaptive Biotechnology for TCR repertoire. (A) Number of T-cell clones that make up 25% of the TCR repertoire (n=3 mice per group). Red represents the most abundant T-cell clone in the individual mouse tumor; blue is the second most abundant; teal is the third. (B) Table of the average number of clones from three mice per group that make up 25% of the TCR repertoire. IL12, interleukin-12; i.p. intraperitoneally; s.c., subcutaneously; TCR, T-cell receptor.